Heart Failure Biomarkers in Hemodialysis Patients

Overview

Journal Cardiol J

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 12

PMID 38994825

Authors

Zbigniew Heleniak

Michal Bohdan

Marcin Gruchala

Alicja Debska-Slizien

Affiliations

Soon will be listed here.

Abstract

The diagnosis of end-stage renal disease (ESRD) is made when the estimated glomerular filtration rate is less than 15 mL/min/1.73 m2. Most patients with that stage of chronic kidney disease (CKD) are eligible for renal replacement treatment, which includes kidney transplantation, hemodialysis and peritoneal dialysis. It is well recognized that CKD raises the risk of cardiovascular disease and is linked to a higher cardiovascular death rate in this population. Additionally, the largest risk of cardiovascular events is seen in ESRD patients. Heart failure (HF) and dangerous arrhythmias, which are more common in the advanced stages of CKD, are two additional causes of cardiovascular death in addition to atherosclerosis-related complications such as myocardial infarction and stroke. In this review the significance of natriuretic peptides and other HF biomarkers in hemodialysis patients, as tools for cardiovascular risk assessment will be discussed.

Citing Articles

Analysis of research trends and hotspots in the primary treatment of end-stage renal disease.

Shi L, Wang J, Wei T, Liang Z, Zhang L, Li C Int Urol Nephrol. 2024; .

PMID: 39589637 DOI: 10.1007/s11255-024-04290-4.

References

Liyanage T, Ninomiya T, Jha V, Neal B, Patrice H, Okpechi I . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981):1975-82. DOI: 10.1016/S0140-6736(14)61601-9. View

Gardner R, Ozalp F, Murday A, Robb S, McDonagh T . N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003; 24(19):1735-43. DOI: 10.1016/j.ehj.2003.07.005. View

Breit S, Carrero J, Tsai V, Yagoutifam N, Luo W, Kuffner T . Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant. 2011; 27(1):70-5. DOI: 10.1093/ndt/gfr575. View

. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl (2011). 2015; 3(1):91-111. PMC: 4284425. DOI: 10.1038/kisup.2012.67. View

Madsen L, Ladefoged S, Corell P, Schou M, Hildebrandt P, Atar D . N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007; 71(6):548-54. DOI: 10.1038/sj.ki.5002087. View

Dickey D, Potter L . ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency. Clin Chem. 2011; 57(9):1272-8. PMC: 4855511. DOI: 10.1373/clinchem.2011.169151. View

Henderson N, MacKinnon A, Farnworth S, Kipari T, Haslett C, Iredale J . Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008; 172(2):288-98. PMC: 2312353. DOI: 10.2353/ajpath.2008.070726. View

Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C . A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur J Intern Med. 2017; 44:31-38. DOI: 10.1016/j.ejim.2017.05.027. View

Yang W, Fahim M, Johnson D . Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease. Clin Biochem. 2020; 83:1-11. DOI: 10.1016/j.clinbiochem.2020.05.013. View

10.

Wollert K, Kempf T . Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep. 2012; 9(4):337-45. DOI: 10.1007/s11897-012-0113-9. View

11.

Gohar A, Rutten F, den Ruijter H, Kelder J, von Haehling S, Anker S . Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail. 2019; 21(10):1219-1227. DOI: 10.1002/ejhf.1495. View

12.

Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O . Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail. 2007; 13(2):120-7. DOI: 10.1016/j.cardfail.2006.10.014. View

13.

Biollaz J, Callahan 3rd L, Nussberger J, Waeber B, Gomez H, Blaine E . Pharmacokinetics of synthetic atrial natriuretic peptides in normal men. Clin Pharmacol Ther. 1987; 41(6):671-7. DOI: 10.1038/clpt.1987.94. View

14.

Artunc F, Mueller C, Breidthardt T, Twerenbold R, Rettig I, Usta E . Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker?. Kidney Blood Press Res. 2012; 36(1):172-81. DOI: 10.1159/000343406. View

15.

Schlittenhardt D, Schober A, Strelau J, Bonaterra G, Schmiedt W, Unsicker K . Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004; 318(2):325-33. DOI: 10.1007/s00441-004-0986-3. View

16.

Damman K, Valente M, Voors A, OConnor C, Van Veldhuisen D, Hillege H . Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2013; 35(7):455-69. DOI: 10.1093/eurheartj/eht386. View

17.

Hassan K, Hassan S, Anwar S, Zaher A, Edgem R, Hassan F . Predictors of left ventricular hypertrophy and their cutoffs in peritoneal dialysis patients. Int Heart J. 2015; 56(2):186-91. DOI: 10.1536/ihj.14-246. View

18.

. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 45(4 Suppl 3):S1-153. View

19.

Nongnuch A, Panorchan K, Davenport A . Predialysis NTproBNP predicts magnitude of extracellular volume overload in haemodialysis patients. Am J Nephrol. 2014; 40(3):251-7. DOI: 10.1159/000368376. View

20.

Zhang Z, Shen B, Cao X, Liu Z, Chen X, Nie Y . Increased Soluble Suppression of Tumorigenicity 2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study. Blood Purif. 2016; 43(1-3):37-45. DOI: 10.1159/000452924. View